Polyrizon Ltd. (PLRZ)
PLRZNASDAQ-CMMedical/Dental Instruments
$11.10
+0.0500 (+0.45%) today
Regular session, Nov 10, 2:26 PM ET
- Market cap
- $26.96m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $10.57 to $11.11
- 52-week range
- $2.88 to $18.20
- Average volume
- 42.2k
- Previous close
- $11.05
Financials
| Quarter | Dec 2021 |
|---|---|
| Revenue | – |
| Gross profit | – |
| Operating income | -$703.0k |
| Net income | -$711.0k |
News
8 latest- Polyrizon Files New U.S. Patent Application Covering Nasal Drug Delivery RTTNews · Oct 5, 2026
- Polyrizon Reports Enrollment Of First Patient In Trial For Allergy Nasal Spray NASARIX RTTNews · Sep 22, 2026
- Polyrizon Announces $4 Mln Registered Direct Offering And Private Placement RTTNews · Sep 3, 2026
- Polyrizon Completes Clinical Site Contracting For NASARIX Trial; Advances Into FIH Study Execution RTTNews · Sep 2, 2026
- Polyrizon Finalizes U.S. Clinical Sites For NASARIX Allergy Study RTTNews · Aug 20, 2026
- Polyrizon Gains Central IRB Approval For First-in-Human NASARIX Trial In Allergic Rhinitis; Stock Up RTTNews · Jun 29, 2026
- Top Biotech Gainers: QURE Rallies On AMT-130 Update, LNAI On Track, FTH Eyes Q4 Data, ELTX On Watch RTTNews · Jun 17, 2026
- Top Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On Watch RTTNews · May 26, 2026
The company
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon's proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a 'biological mask' with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-CM
- Region
- Middle East
- Website
- polyrizon-biotech.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.